An Interview with Peptides Industry Leader Paul Feldman, Senior Vice President, GSK

Oxford Global Conferences are proud to present the 2nd Annual Peptides Congress, taking place at the Novotel London West on the 20^th and 21^st April 2015. The conference provides an exclusive opportunity for over 350 experts working in different areas of the peptides industry to exchange their experiences, engage in scientific discussions and network with senior-level attendees about the most pressing challenges of the industry. The two day congress is co-located with our 8^th Annual Proteins and Antibodies Congress and our 3^rd Annual Biosimilars and Biobetters Congress. In the run up to our highly anticipated 2nd Annual Peptides Congress, we asked industry key opinion leader Paul Feldman, Senior Vice President, GSK a few questions about the peptides industry and his recent research results…

 

What new risks are scientists at GSK facing in the future discovery and development of new medicines to treat metabolic diseases?

 

“At GSK, the group I lead is seeking to discover combination peptides that will treat metabolic diseases. Specifically, there’s a significant unmet medical need for the treatment of type 2 diabetes and obesity, which is based on the increased incidence of both of these diseases. There are a number of assets that are on the market for treating type 2 diabetes, making it a bit more competitive; however there remains the opportunity to discover and develop medicines that are differentiated from assets on the market.

 

For the treatment of obesity there is a far fewer assets on the market, and thus, the opportunity for new, effective medicines is significant. Although the opportunity is great for new medicines to treat type 2 diabetes and obesity these are also very high risk, high reward areas. What I mean by this is that you have to have molecules that are very safe and molecules that are very effective. This requires a very significant investment in large clinical studies. Although it is a high reward area coupled with high unmet medical need, it’s also associated with a very high cost of drug development.”

 

At our upcoming 2^nd Annual Peptides Congress you will be delivering a presentation about enteroendocrine peptide drug discovery for the treatment of metabolic diseases. What are the specific challenges you are currently facing?

 

“In my group, we’re working on discovering new agents to treat type 2 diabetes and obesity. In order to meet the significant efficacy hurdles, we’re working on combination agents. Based on the data we’ve collected, and this is the data I present at the congress, we believe that one can generate combination assets that show significant promise to have transformational efficacy. By developing combination agents however; it also leads to greater complexity from a development standpoint. This means you have two novel agents that increase not only the cost but also the complexity of the clinical development and your regulatory pathway.”

 

To read the full interview with Paul Feldman  please visit:

http://www.peptides-congress.com/who-is-speaking/q-a/

 

If you would like to hear more from Paul Feldman, he will be presenting his research on the “Enteroendocrine Peptide Drug Discovery For Treatment Of Metabolic Diseases” on the 21^st April 2015 in the Peptides stream.

 

Oxford Global Conferences are proud to announce the following speakers for The 2^nd Annual Peptides Congress:

 

Joel Richard Senior Vice President, Peptides – Head of CMCE Dreux Site, Ipsen, presenting on oral peptide delivery

Konrad Bleicher Peptide Area Head Discovery Chemistry, pRED, Roche Innovation Centre Basel addressing designed pharmacology

Michael Wagner Director Medicinal Chemistry, Head of Peptides, Novartis Pharma AG demonstrating the recent progress in peptide sustained release approaches

 

For a full list of our congress speakers and to download the agenda please visit:

www.peptides-congress.com/download-agenda-marketing

 

For further information or to enquire about available discounts please contact Steph Punfield on s.punfield@oxfordglobal.co.uk or phone us on +44(0)1865 248455

 

Post-Congress Seminar

22^nd April 2015 in London, UK

 

~PEPTIDES~

 

This one day course is limited to only 15 delegate places and is designed to be highly interactive with open discussions and practical advice. Topics include; Peptides: What Are They and Why Should You Care?  Peptide Development and Engineering, Peptide Delivery Systems and The Cutting Edge of Peptide Research. Upon registration delegates are provided with a pre-seminar questionnaire to allow the trainer to tailor the day to your needs of understanding specifics of the industry.

 

The standard price to attend our post congress seminar is £699 + VAT. Please contact Steph Punfield to receive further information or to enquire about available discounts on s.punfield@oxfordglobal.co.uk or call +44(0)1865 248455. Places are limited and discounts are available on a first come first served basis.

 

1. Stephanie Punfield. Marketing Executive. +44(0) 1865 248455. S.punfield@oxfordglobal.co.uk

2. Oxford Global Conferences produces cutting edge congresses and summits for the Life Sciences Industry.

3. Oxford Global Conferences Ltd. phone +44 (0)1865 248455 | fax +44 (0)1865 250985 | email: info@oxfordglobal.co.uk  | Web: http://www.oxfordglobal.co.uk/